MENU

NURO Stock Tickeron detected bearish Stock Pattern: Three Falling Peaks NURO on April 08, 2025, netting in a 0.71% gain over 3 weeks

A.I.dvisor
at Tickeron.com
Loading...
+0.71% Gain from a Successful pattern Three Falling Peaks
NURO - NeuroMetrix
Tickeron
Ticker: NURO
Company: NeuroMetrix
Gain from shorting: +0.71%
Confirmed: 04/08/25
Succeeded: 04/08/25
Total length: 26 days
On March 13, 2025, A.I.dvisor detected a Three Falling Peaks Pattern (Bearish) for NeuroMetrix (NURO, $4.37). 26 days later, on April 08, 2025, A.I.dvisor confirmed the Bearish pattern, setting a target price of the stock. On April 08, 2025, the stock hit the target price of $4.28 – resulting in a gain for traders who shorted the stock on the pattern detection date.

Momentum Indicator for NURO turns negative, indicating new downward trend

NURO saw its Momentum Indicator move below the 0 level on April 03, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In of the 104 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for NURO moved out of overbought territory on March 25, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Moving Average Convergence Divergence Histogram (MACD) for NURO turned negative on March 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NURO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NURO broke above its upper Bollinger Band on March 24, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 59 cases where NURO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

NURO moved above its 50-day moving average on April 10, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NURO advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 94 cases where NURO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.401) is normal, around the industry mean (23.728). P/E Ratio (0.000) is within average values for comparable stocks, (81.831). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (0.717) is also within normal values, averaging (41.794).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NURO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NURO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.

View a ticker or compare two or three
NURO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of medical devices used for treatment of the neurological complications of diabetes

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
Medical Specialties
Address
4B Gill Street
Phone
+1 781 890-9989
Employees
26
Web
https://www.neurometrix.com